Literature DB >> 12164688

Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Mart A A M Heesters1, Jan Koudstaal, K Gwan Go, Willemina M Molenaar.   

Abstract

Identification of patients with a low grade glioma with a long-term recurrence-free survival is of clinical value as radiotherapy can be postponed until recurrence. The recurring glioma may increase in malignancy compared to the original tumor, which is possibly related to radiotherapy. We studied proliferation by counting mitotic figures and by MIB-1 labeling, apoptosis by TUNEL and expression of proteins related to cell cycle regulation by immunohistochemical analysis of p53, p21, bcl-2 and bax expression in 48 low grade gliomas. Astrocytomas (A, n = 14) and oligodendrogliomas (O, n = 4) with a recurrence-free survival of more than 9 years after surgery had a signficantly lower p53 index compared to A (n = 18) and O (n = 12) with a histopathologically documented recurrence. Additionally, the recurrence-free A had a higher p21 index. No significant differences were observed in MIB-LI, TUNEL-LI, bcl-2 and bax expression. Initially low grade gliomas and their corresponding recurrences were compared (n = 30). In the gliomas without radiotherapy (n = 15), no differences in mitotic rate, TUNEL-LI, p53, p21, bcl-2 and bax expression were found between primary tumors and their recurrences. Only MIB-LI was higher in the recurrent tumors. In the gliomas with radiotherapy (n = 15) no differences were detected in these parameters between the original tumor and the recurrent tumor except for a higher number of mitoses in the recurrent tumors. We conclude that low grade gliomas with a long-term recurrence-free survival were characterized by a low p53 protein expression and, in the case of A, a higher p21 index. We found no evidence that radiotherapy is involved in changes of proliferation, apoptosis or expression of proteins related to cell cycle regulation in recurring gliomas.

Entities:  

Mesh:

Year:  2002        PMID: 12164688     DOI: 10.1023/a:1016046125698

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

1.  Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines.

Authors:  S J DiBiase; J Guan; W J Curran; G Iliakis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

2.  Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas.

Authors:  C Hagel; G Laking; R Laas; S Scheil; R Jung; K Milde-Langosch; D K Stavrou
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

Review 3.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction.

Authors:  W C Broaddus; Y Liu; L L Steele; G T Gillies; P S Lin; W G Loudon; K Valerie; R K Schmidt-Ullrich; H L Fillmore
Journal:  J Neurosurg       Date:  1999-12       Impact factor: 5.115

5.  Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era.

Authors:  S Rudoler; B W Corn; M Werner-Wasik; A Flanders; P E Preston; L Tupchong; W J Curran
Journal:  Am J Clin Oncol       Date:  1998-02       Impact factor: 2.339

6.  Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors.

Authors:  A Hara; Y Hirose; N Yoshimi; T Tanaka; H Mori
Journal:  Neurol Res       Date:  1997-12       Impact factor: 2.448

Review 7.  The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.

Authors:  R G Bristow; S Benchimol; R P Hill
Journal:  Radiother Oncol       Date:  1996-09       Impact factor: 6.280

8.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

9.  p53 mutations increase resistance to ionizing radiation.

Authors:  J M Lee; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

10.  p53 protein in low-grade astrocytomas: a study with long-term follow-up.

Authors:  P Iuzzolino; C Ghimenton; A Nicolato; F Giorgiutti; P Fina; C Doglioni; M Barbareschi
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  3 in total

1.  Apoptosis and proliferation: correlation with p53 in astrocytic tumours.

Authors:  Chitra Sarkar; Asis Kumar Karak; Neera Nath; Mehar Chand Sharma; Ashok Kumar Mahapatra; Parthoprasad Chattopadhyay; Subrata Sinha
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

Review 2.  Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Brian V Nahed; Navid Redjal; Daniel J Brat; Andrew S Chi; Kevin Oh; Tracy T Batchelor; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

3.  Correlation of in vitro infiltration with glioma histological type in organotypic brain slices.

Authors:  S Palfi; K R Swanson; S De Boüard; F Chrétien; R Oliveira; R K Gherardi; J M Kros; M Peschanski; C Christov
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.